All In Biotech

Drug Trial Radar · NCT07947056

A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin

A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Jun 6, 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Tuberculosis Research Centre, IndiaGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.

Conditions

  • Tuberculosis, Pulmonary, Drug Sensitive

Interventions

  • Standard 6-month treatment regimenDrug

    Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol

  • High dose Rifampicin (25mg/Kg)Drug

    Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

  • High dose Rifampicin (25mg/Kg)Drug

    Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

  • High dose Rifamipicn (25mg/Kg) & LevofloxacinDrug

    Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomizationTime frame: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • All India Institute of Medical Sciences(AIIMS), Mangalagiri

    Guntur, Andhra Pradesh, India · Recruiting

  • All India Institute of Medical Sciences, Guwahati

    Guwahati, Assam, India · Active not recruiting

  • Govt. PDU Medical College

    Rajkot, Gujarat, India · Not yet recruiting

  • Govt. Medical College and NCH

    Surat, Gujarat, India · Active not recruiting

  • Grant Govt. Medical College & Sir JJ Group of Hospitals

    Mumbai, Maharashtra, India · Recruiting

  • All India Institute Of Medical Sciences, Nagpur

    Nagpur, Maharashtra, India · Not yet recruiting

  • North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)

    Shillong, Meghālaya, India · Recruiting

  • National Institute of TB and Respiratory Diseases

    New Delhi, National Capital Territory of Delhi, India · Not yet recruiting

  • Post Graduate Institute of Medical Education & Research, Capital Hospital

    Bhubaneswar, Odisha, India · Active not recruiting

  • All India Institute of Medical Sciences (AIIMS), Bhubaneswar

    Bhubaneswar, Odisha, India · Active not recruiting

  • ICMR - National Institute for Research in Tuberculosis

    Chennai, Tamil Nadu, India · Recruiting

  • Govt. General and Chest Hospital, Osmania Medical College

    Hyderabad, Telangana, India · Recruiting

  • Sarojini Naidu Medical College

    Agra, Uttar Pradesh, India · Recruiting

  • Moti Lal Nehru Medical College

    Allahābād, Uttar Pradesh, India · Recruiting

  • King George Medical University

    Lucknow, Uttar Pradesh, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.